Results 191 to 200 of about 104,993 (291)

Cognitive screening biases in a secondary prevention Alzheimer's disease clinical trial

open access: yesAlzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) prevention trials have multiple steps to identify cognitively unimpaired individuals with AD biomarker evidence. Cognitive/functional screening tests may be biased in ethnoracial minorities, impacting trial eligibility.
Isha Sai   +7 more
wiley   +1 more source

Parental Knowledge and Acceptance of Pediatric Lumbar Puncture in Northern Saudi Arabia: Implications for Clinical Practice and Education: A Cross-Sectional Study. [PDF]

open access: yesPediatr Rep
Alenezi DFK   +12 more
europepmc   +1 more source

Plasma inflammatory biomarker profiles across the Alzheimer's disease spectrum in the Bio‐Hermes cohort

open access: yesAlzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract INTRODUCTION Inflammation contributes to Alzheimer's disease (AD), but its stage‐specific and amyloid‐dependent patterns remain unclear. METHODS We analyzed 964 participants from the Bio‐Hermes cohort (cognitively normal [CN] = 404, mild cognitive impairment [MCI] = 302, mild AD = 258). Plasma levels of 32 cytokines, neurofilament light chain (
Zain Hussain   +5 more
wiley   +1 more source

Nonionic contrast neurotoxicity after coronary angiography mimicking subarachnoid hemorrhage [PDF]

open access: yes, 2003
Hamann, Gerhard F.   +4 more
core   +1 more source

Multivariate patterns of plasma biomarkers predict region‐specific Alzheimer's pathology and cognitive decline across independent cohorts

open access: yesAlzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) is characterized by the progressive accumulation of amyloid‐beta (Aβ) plaques, tau tangles, and neurodegeneration (ATN framework). While neuroimaging detects these changes, it is costly and not widely accessible. Blood‐based biomarkers offer scalable alternatives for early detection.
Jafar Zamani   +4 more
wiley   +1 more source

Obstructive sleep apnea severity, Alzheimer's disease plasma markers, and CSF brain amyloidosis and tau pathology

open access: yesAlzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract INTRODUCTION We examined obstructive sleep apnea (OSA) severity's association with Alzheimer's disease (AD) plasma biomarkers, independent or synergistic with cerebrospinal fluid (CSF) amyloid, and as a proof of concept, whether plasma amyloid beta (Aβ)42/Aβ40 with OSA severity improves detection of amyloidosis and tau pathology.
Omonigho Michael Bubu   +25 more
wiley   +1 more source

Combining blood biomarkers and the German version of the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID‐G) for diagnosing cognitive decline in Down syndrome

open access: yesAlzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract INTRODUCTION Individuals with Down syndrome (DS) are at risk for Alzheimer's disease (AD). However, diagnosis remains challenging due to variability of intellectual ability and symptom presentation. To investigate whether serum AD biomarkers enhance accuracy of the German version of the Dementia Screening Questionnaire for Individuals with ...
Olivia Wagemann   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy